2:41 PM
Nov 08, 2018
 |  BC Innovations  |  Product R&D

JLABS seeks lung cancer solutions in Shanghai

Why JLABS Shanghai Head Sharon Chan sees lung cancer as a priority

As Johnson & Johnson gears up to launch its Shanghai JLABS site early next year, the incubator’s head, Sharon Chan, has pegged lung cancer as one of the first priorities.

Chan sees opportunity in China in multiple fields, as the country builds capabilities in artificial intelligence and big data. The prevalence of lung cancer means J&J can compete in an indication where it’s been late to the party in the U.S.

J&J has no marketed therapies in lung cancer, and has a Phase II program on the FGFR inhibitor erdafitinib, and a Phase I program on JNJ-61186372, a bispecific antibody against EGFR and c-MET.

On Nov. 5, J&J’s Janssen Pharmaceuticals Inc. unit announced a deal with South Korean biotech Yuhan Corp. to license the Phase I/II non-small cell lung cancer (NSCLC) therapy lazertinib. Janssen will receive exclusive rights to develop and commercialize lazertinib worldwide, except in South Korea, and is responsible for development, manufacturing and commercialization of the product.

JLABS @ Shanghai is scheduled to launch in 2Q19. It will be the twelfth JLABS center, and the first in Asia. It will be located in Zhangjiang Hi-Tech Park along with Janssen Discovery Center, close to J&J’s consumer innovation-focused Shanghai Technology and Research Center (STAR) and J&J’s medical device research center. The JLABS site will host up to 50 life science and healthcare start-ups.

Companies housed in the incubator will be able to tap into resources from J&J’s Asia innovation hub, which includes its Asia Pacific Innovation Center, Janssen China Discovery Lab, and STAR. Companies will have access to lab space, core equipment and operational management support.

Collectively, the no-strings-attached incubators have housed over 420 pharmaceutical, diagnostic and other healthcare companies.

BioCentury spoke with Chan about why this was a good time to launch a JLABS in Shanghai and her plans for the incubator....

Read the full 1516 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >